Jackson M R, Friedman S A, Carter A J, Bayer V, Burge J R, MacPhee M J, Drohan W N, Alving B M
Department of Hematology and Vascular Biology, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.
J Vasc Surg. 1997 Aug;26(2):274-80. doi: 10.1016/s0741-5214(97)70189-7.
The efficacy of currently available topical hemostatic agents requires the formation of fibrin generated from circulating blood. Fibrin sealant, which is prepared from high concentrations of thrombin and fibrinogen, has been used in liquid form to promote hemostasis during vascular surgery. In a blinded, randomized, placebo-controlled fashion, we evaluated a dry dressing of purified, viral-inactivated human fibrinogen and human thrombin in a large animal model of arterial injury.
Dressings were prepared by application of a layer of lyophilized human fibrin sealant or immunoglobulin G (IgG, control) to a silicone backing material. Six anesthetized female Yorkshire pigs (16 to 27 kg) received bilateral, 4 mm longitudinal femoral arteriotomies after surgical exposure of the arteries. The arteriotomies were not closed. In each animal a fibrin sealant dressing was applied to one artery and a control dressing to the other. Each dressing was secured on the arteriotomy by a mechanical device. After application of the dressings, blood flow was restored to each limb for 1 hour. The compressive device was released for 5 seconds at intervals of 15 minutes to assess hemostasis. Blood flow was measured distal to each arteriotomy with a dual-channel flowmeter to adjust equal bilateral compression.
Blood loss (mean +/- SEM) was significantly less from the arteriotomy treated with the fibrin-based dressing compared with the control dressing (4.9 +/- 4.0 ml versus 82.3 +/- 11.1 ml; p = 0.0005). Complete hemostasis was achieved at the first 15-minute interval in five of six arteriotomies treated with fibrin sealant and in none of the six control arteriotomies during 1 hour of assessment (p = 0.03). Blood flow through each femoral artery at baseline was the same in both treatment and control arteries (fibrin sealant, 114.2 +/- 17.4 ml/min; control, 106.7 +/- 16.5 ml/min; p = 0.24) and was not significantly different throughout the experiment.
Fibrin-based dressings provide effective hemostasis in a large animal model of arterial injury. Further development of these dressings will address optimal formulation and configuration for clinical use. Our results suggest that fibrin-based dressings will be effective in promotion of hemostasis in arterial bleeding, without compromising blood flow.
目前可用的局部止血剂的功效需要由循环血液产生的纤维蛋白形成。由高浓度凝血酶和纤维蛋白原制备的纤维蛋白密封剂已以液体形式用于血管手术中促进止血。我们以盲法、随机、安慰剂对照的方式,在大型动脉损伤动物模型中评估了纯化的、病毒灭活的人纤维蛋白原和人凝血酶的干敷料。
通过将一层冻干的人纤维蛋白密封剂或免疫球蛋白G(IgG,对照)应用于硅胶背衬材料来制备敷料。六只麻醉的雌性约克夏猪(16至27千克)在动脉手术暴露后接受双侧4毫米纵向股动脉切开术。动脉切开术未闭合。在每只动物中,将纤维蛋白密封剂敷料应用于一条动脉,将对照敷料应用于另一条动脉。每个敷料通过机械装置固定在动脉切开处。敷料应用后,恢复每个肢体的血流1小时。每隔15分钟释放压迫装置5秒钟以评估止血情况。使用双通道流量计测量每个动脉切开术远端的血流,以调整双侧相等的压迫。
与对照敷料相比,用基于纤维蛋白的敷料治疗的动脉切开术的失血量(平均值±标准误)明显更少(4.9±4.0毫升对82.3±11.1毫升;p = 0.0005)。在评估的1小时内,用纤维蛋白密封剂治疗的六个动脉切开术中的五个在第一个15分钟间隔时实现了完全止血,而六个对照动脉切开术中没有一个实现完全止血(p = 0.03)。治疗组和对照组动脉在基线时通过每条股动脉的血流相同(纤维蛋白密封剂,114.2±17.4毫升/分钟;对照,106.7±16.5毫升/分钟;p = 0.24),并且在整个实验过程中没有显著差异。
基于纤维蛋白的敷料在大型动脉损伤动物模型中提供有效的止血作用。这些敷料的进一步开发将解决临床使用的最佳配方和配置问题。我们的结果表明,基于纤维蛋白的敷料在促进动脉出血止血方面将是有效的,而不会影响血流。